Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Conclusions. The MTD and RP2D could not be established as the study closed early due to the absence of a dose –response relationship and non-optimal PK profile. No further clinical development of M3541 was pursued. (Trial registration number ClinicalTrials.gov NCT03225105. Registration date July 21, 2017).

http://link.springer.com/10.1007/s10637-022-01216-8

Source: Investigational New Drugs - February 12, 2022 Category: Drugs & Pharmacology Source Type: research